EGFR and laryngotracheoesophageal cleft: Studies conducted by researchers from various countries have duly ascertained the crucial significance of miRNAs in the development of resistance against gefitinib and erlotinib, thereby positing that targeting these specific miRNAs could potentially serve as a highly efficacious therapeutic approach for patients afflicted with first-generation EGFR-TKI-resistant LC.